Phase 1 Study of ABT‐751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer

ABT‐751 is an orally bioavailable sulfonamide with antimitotic properties. A nonrandomized phase 1 dose‐escalation study of ABT‐751 in combination with CAPIRI (capecitabine and irinotecan) and bevacizumab was conducted to define the maximum tolerated dose, dose‐limiting toxicity (DLT), and pharmacok...

Descripción completa

Detalles Bibliográficos
Autores principales: Rudek, Michelle A., Dasari, Arvind, Laheru, Daniel, He, Ping, Jin, Runyan, Walker, Rosalind, Taylor, Gretchen E., Jimeno, Antonio, Donehower, Ross C., Hidalgo, Manuel, Messersmith, Wells A., Purcell, W. Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892995/
https://www.ncbi.nlm.nih.gov/pubmed/26632033
http://dx.doi.org/10.1002/jcph.681

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892995/
https://www.ncbi.nlm.nih.gov/pubmed/26632033
http://dx.doi.org/10.1002/jcph.681

Ejemplares similares